Ohio Democrat state Rep. Tavia Galonski tweeted she will make a referral for a “crimes against humanity” charge against President Trump for touting hydroxychloroquine as a potential coronavirus treatment.
I can’t take it anymore. I’ve been to The Hague. I’m making a referral for crimes against humanity tomorrow. Today’s press conference was the last straw. I know the need for a prosecution referral when I see one.
I can’t take it anymore. I’ve been to The Hague. I’m making a referral for crimes against humanity tomorrow. Today’s press conference was the last straw. I know the need for a prosecution referral when I see one. https://t.co/XQin24gqY4
— Rep. Tavia Galonski (@RepGalonski) April 6, 2020
Per Newsweek, the U.S. is facing shortages of antimalarial drugs being used experimentally to treat COVID-19 patients, according to the Food and Drug Administration (FDA).
Both hydroxychloroquine and chloroquine, which are used to treat malaria, lupus and rheumatoid arthritis, are listed as “currently in shortage” by the agency. This is “due to a significant surge in demand,” the body said.
The FDA stated: “all manufacturers are ramping up production” and the agency is ensuring this is happening “expeditiously and safely.”
The announcement follows FDA approval of the drugs for use in patients hospitalized by and in clinical trials for the treatment of COVID-19, after it issued the first Emergency Use Authorization for a drug related to the disease over the weekend.
The U.S. Department of Health and Human Services (HHS) said in a statement on Sunday that it accepted 30 million doses of hydroxychloroquine sulfate from an arm of the pharmaceutical company Novartis, and one million of chloroquine phosphate from Bayer Pharmaceuticals.
On Wednesday, the FDA said the 30 million doses “is expected to help ease supply pressures for the drugs.
“This is a fluctuating and dynamic situation and the FDA is actively engaged. The agency is updating its shortages lists regularly and continuing to communicate in real-time so that patients and healthcare providers have the most current information on product shortages in the U.S.”